Lanean...
The efficacy and safety of combination of PD-1 and CTLA-4 inhibitors: a meta-analysis
BACKGROUND: Recently, a series of clinical trials showed that combination of anti-programmed cell death-1 (α-PD-1) and anti-cytotoxic T-lymphocyte-associated protein 4 (α-CTLA-4) could effectively eliminate tumor. However, in comparison with widely adopted mono-immune checkpoint inhibitors, chemothe...
Gorde:
| Argitaratua izan da: | Exp Hematol Oncol |
|---|---|
| Egile Nagusiak: | , , , , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
BioMed Central
2019
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6815037/ https://ncbi.nlm.nih.gov/pubmed/31673481 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40164-019-0150-0 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|